XML 37 R21.htm IDEA: XBRL DOCUMENT
v3.6.0.2

Note 15 - Revenue by Product Group, by Significant Customer and by Geographic Location; Geographic Information | 12 Months Ended
--- | ---
Dec. 31, 2016
Notes to Financial Statements |
Segment Reporting Disclosure [Text Block] | 15. Revenue by Product Group, by Significant Customer and by Geographic Location; Geographic Information Product revenue by product group is as follows:
|  | Years Ended December 31,
|  | 2016 |  | 2015 |  | 2014
|  | Revenue |  | Percentage of Product Revenue |  | Revenue |  | Percentage of Product Revenue |  | Revenue |  | Percentage of Product Revenue
Orthobiologics |  | $ | 89,695 |  |  |  | 87 | % |  | $ | 73,247 |  |  |  | 84 | % |  | $ | 61,957 |  |  |  | 82 | %
Dermal |  |  | 2,759 |  |  |  | 3 | % |  |  | 2,266 |  |  |  | 2 | % |  |  | 1,334 |  |  |  | 2 | %
Surgical |  |  | 5,427 |  |  |  | 5 | % |  |  | 5,812 |  |  |  | 7 | % |  |  | 5,855 |  |  |  | 8 | %
Other |  |  | 5,051 |  |  |  | 5 | % |  |  | 6,371 |  |  |  | 7 | % |  |  | 6,328 |  |  |  | 8 | %
|  | $ | 102,932 |  |  |  | 100 | % |  | $ | 87,696 |  |  |  | 100 | % |  | $ | 75,474 |  |  |  | 100 | %
Product revenue from our sole significant customer, Mitek, as a percentage of our total product revenue was 75%, 72%, and 72% for the years ended December 31, 2016, 2015, and 2014, respectively. In December 2011, the Company entered into a fifteen -year licensing agreement (the “Mitek MONOVISC Agreement”) with DePuy Synthes Mitek Sports Medicine, a division of DePuy Orthopaedics, Inc., to exclusively market MONOVISC in the U.S. The Company received an upfront payment of $2.5 million in December 2011. This non-refundable upfront payment did not have standalone value without Anika’s completion of development obligations, which included obtaining regulatory approval of the product and resolving the related patent litigation. As a result, the Company recognized the upfront payment over the development obligation period. During the first quarter of 2014, the Company received FDA approval of MONOVISC and resolved the patent lawsuit with Genzyme Corporation. As a result of the full delivery of its development obligations under this agreement, the Company recognized approximately $2.2 million, which represented the remaining balance of deferred revenue relating to the initial $2.5 million payment. In the first quarter of 2014, the Company also received a milestone payment of $17.5 million as a result of achieving FDA approval for MONOVISC and resolving the patent litigation with Genzyme. This milestone payment was fully recognized as revenue during the three months ended March 31, 2014. On April 15, 2014 the first U.S. commercial sale of MONOVISC was made by the Company’s commercial partner, Mitek. Under the terms of the Mitek MONOVISC Agreement, the Company earned and collected a milestone payment of $5 million, which was fully recognized as revenue in the second quarter of 2014. On November 10, 2014, the Center for Medicare & Medicaid Services ("CMS") assigned a unique Healthcare Common Procedure Coding System ("HCPCS") code, or J-Code, to MONOVISC. The issuance of this code by CMS set national Medicare reimbursement rates for the product. The new J-Code became effective on January 1, 2015. As a result of CMS assigning the J-Code, the Company collected a milestone payment of $5.0 million, which was fully recognized as revenue in the fourth quarter of 2014. During the fourth quarter of 2015, the Company collected and fully recognized revenue for a milestone payment of $5.0 million as a result of U.S. MONOVISC 12 month rolling end-user sales exceeding $50 million. For the year ended December 31, 2015, the Company recognized a total of $5.0 million in milestone revenue related to MONOVISC. The Company did not recognize any milestone revenue associated with this contract for the year ended December 31, 2016. Total revenue by geographic location based on the location of the customer in total and as a percentage of total revenue are as follows:
|  | Years Ended December 31,
|  | 2016 |  | 2015 |  | 2014
|  | Total Revenue |  | Percentage of Revenue |  | Total Revenue |  | Percentage of Revenue |  | Total Revenue |  | Percentage of Revenue
Geographic Location: |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
United States |  | $ | 83,972 |  |  |  | 81 | % |  | $ | 76,621 |  |  |  | 82 | % |  | $ | 92,259 |  |  |  | 87 | %
Europe |  |  | 10,953 |  |  |  | 11 | % |  |  | 8,756 |  |  |  | 9 | % |  |  | 6,215 |  |  |  | 6 | %
Other |  |  | 8,454 |  |  |  | 8 | % |  |  | 7,622 |  |  |  | 9 | % |  |  | 7,121 |  |  |  | 7 | %
Total |  | $ | 103,379 |  |  |  | 100 | % |  | $ | 92,999 |  |  |  | 100 | % |  | $ | 105,595 |  |  |  | 100 | %
The Company recorded licensing, milestone, and contract revenue of $0.4 million, $5.3 million and $30.1 million for the years ended December 31, 2016, 2015, and 2014, respectively. Substantially all licensing, milestone, and contract revenue was derived in the United States for each year presented. Net long-lived assets, consisting of net property and equipment, are subject to geographic risks because they are generally difficult to move and to effectively utilize in another geographic area in a reasonable time period and because they are relatively illiquid. See Note 11, Commitments and Contingencies , for more information regarding the build-to-suit lease agreement with Zip resulting in an increase in net property and equipment in Italy. Net tangible long-lived assets by principal geographic areas are as follows:
|  | Years Ended December 31,
|  | 2016 |  | 2015
United States |  | $ | 49,140 |  |  | $ | 39,732 |
Italy |  |  | 3,156 |  |  |  | 376 |
Total |  | $ | 52,296 |  |  | $ | 40,108 |

X
- References No definition available. + Details
Name: | us-gaap_DisclosureTextBlockAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 34 -URI http://asc.fasb.org/extlink&oid=68060357&loc=d3e8981-108599 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 41 -URI http://asc.fasb.org/extlink&oid=68060357&loc=d3e9038-108599 Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 33 -URI http://asc.fasb.org/extlink&oid=68060357&loc=d3e8971-108599 Reference 4: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 12 -URI http://asc.fasb.org/extlink&oid=68060357&loc=d3e8595-108599 Reference 5: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 1 -URI http://asc.fasb.org/extlink&oid=68060357&loc=d3e8380-108599 Reference 6: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 32 -URI http://asc.fasb.org/extlink&oid=68060357&loc=d3e8933-108599 Reference 7: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 26 -URI http://asc.fasb.org/extlink&oid=68060357&loc=d3e8844-108599 Reference 8: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 35 -URI http://asc.fasb.org/extlink&oid=68060357&loc=d3e8984-108599 Reference 9: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 40 -URI http://asc.fasb.org/extlink&oid=68060357&loc=d3e9031-108599 Reference 10: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 42 -URI http://asc.fasb.org/extlink&oid=68060357&loc=d3e9054-108599 Reference 11: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 10 -URI http://asc.fasb.org/extlink&oid=68060357&loc=d3e8538-108599 Reference 12: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 29 -URI http://asc.fasb.org/extlink&oid=68060357&loc=d3e8864-108599 Reference 13: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 31 -URI http://asc.fasb.org/extlink&oid=68060357&loc=d3e8924-108599 Reference 14: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 30 -URI http://asc.fasb.org/extlink&oid=68060357&loc=d3e8906-108599 + Details
Name: | us-gaap_SegmentReportingDisclosureTextBlock
Namespace Prefix: | us-gaap_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration